망막분지정맥폐쇄의 황반부종에 대한 유리체강내 베바시주맙 주입술의 효과 = Intravitreal Bevacizumab Injection for Macular Edema Secondary to Branch Retinal Vein Occlusion

국문 초록 (Abstract)

목적: 망막분지정맥폐쇄에서 발생한 황반부종의 치료에 유리체강내에 Bevacizumab 주입술의 효과를 알아보고자 하였다.
대상과 방법: 2006년 12월부터 2007년 6월까지 본원에 내원한 환자 중 20/40 (0.3 logMAR unit)이하의 시력을 보이고, 황반 중심을 침범
한 황반부종이 있는 망막분지정맥폐쇄 환자 중 첫 치료로 유리체강내 Bevacizumab 주입술을 시행한 19명 19안을 대상으로 하였다.
술 전 최대교정시력과 안압을 측정하였으며, 형광안저혈관조영, 광간섭단층촬영을 시행한 후 유리체강내 Bevacizumab을 1회 주입하였
고, 술 후 1, 2, 3, 6개월째 시력 및 황반중심평균두께의 변화를 관찰하였다.
결과: 치료 전 최대교정시력은 1.06 (±0.10 logMAR unit)이었으며 황반중심평균두께는 552.9 μm (±41.0)였다. 치료 후 1개월째 평균
최대교정시력은 0.68 (±0.09 logMAR unit), 2개월째 0.67 (±0.9 logMAR unit), 3개월째 0.61 (±0.09 logMAR unit), 6개월째 0.54 (±0.10
logMAR unit)로 유의한 향상을 보였다. 황반중심평균두께는 치료 후 1개월째 312.0 μm (±41.3)였으며, 3개월째 290.0 μm (±36.7)였고,
6개월째 281.3 μm (±30.1)로 유의한 감소를 보였고, 치료 후 유리체강내 주입에 따른 합병증은 없었다.
결론: 유리체강내 Bevacizumab 주입술은 망막분지정맥폐쇄에서 동반된 황반부종을 감소시키고 시력의 향상을 가져왔다.

다국어 초록 (Multilingual Abstract)

Purpose: To examine the clinical effects of intravitreal bevacizumab injections for patients with macular edema secondary to branched
retinal vein occlusion (BRVO).
Methods: Nineteen patients (19 eyes) diagnosed with BRVO within the three month study window, having visual acuities under 0.5
and significant macular edema within two-disc diameters of the fovea were included in the present study. The author evaluated the
patients’ responses to bevacizumab (1.25 mg/0.05 mL) treatment using visual acuity and central macular edema measurements.
Results: The mean visual acuity improved from 1.06 (±0.10 logMAR unit) at baseline to 0.68 (±0.09 logMAR unit), 0.279 (±0.049)
at one month, 0.67 (±0.9 logMAR unit) at two months, 0.61 (±0.09 logMAR unit) at three months and 0.54 (±0.10 logMAR unit) at
six months. The mean central macular thickness decreased from 552.9 μm (±41.0) at baseline to 290.0 μm (±36.7) at one month,
290.0 μm (±36.7) at three months and 281.3 μm (±30.1) at six months. No adverse side effects were observed following injections.
Conclusions: The observed macular edema and visual acuity improvements, as well as lack of serious adverse side effects after
intravitreal bevacizumab injection, demonstrated that intravitreal bevacizumab injection may be useful for treating patients with macular
edema secondary to BRVO.

참고문헌 (Reference)

• 1 Aiello LP, "Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders" 331 : 1480-1487, 1994
• 2 Wilson CA, "Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation" 110 : 1155-1159, 1992
• 3 Wetzig PC, "The treatment of acute branch vein occlusion by photocoagulation" 87 : 65-73, 1979
• 4 Stefansson E, "The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology" 79 : 435-440, 2001
• 5 Bhavsar AR, "The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials" 144 : 454-456, 2007
• 6 Gutman FA, "The natural course of temporal retinal branch vein occlusion" 78 : OP178-OP192, 1974
• 7 Klein R, "The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study" 98 : 133-141, 2000
• 8 Larsson J, "The 30-Hz flicker cone ERG for monitoring the early course of central retinal vein occlusion" 78 : 187-190, 2000
• 9 Astam N, "Short-term efficacy of intravitreal bevacizumab for the treatment of macular edema due to diabetic retinopathy and retinal vein occlusion" 29 : 543-548, 2009
• 10 Jonas JB, "Safety of intravitreal high-dose reinjections of triamcinolone acetonide" 138 : 1054-1055, 2004
• 11 Chung EJ, "Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion" 246 : 1241-1247, 2008
• 12 Mitchell P, "Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study" 114 : 1243-1247, 1996
• 13 Stewart MW, "Predicted biologic activity of intravitreal bevacizumab" 27 : 1196-1200, 2007
• 14 Rosenfeld PJ, "Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion" 36 : 336-339, 2005
• 15 Jaissle GB, "Ocular side effects and complications of intravitreal triamcinolone acetonide injection" 101 : 121-128, 2004
• 16 Kalogeropoulos C, "Morphology of early retinal lesions after experimental venous occlusion" 208 : 375-376, 1996
• 17 Arnarsson A, "Laser treatment and the mechanism of edema reduction in branch retinal vein occlusion" 41 : 877-879, 2000
• 18 Cekic O, "Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion" 25 : 851-855, 2005
• 19 Chen SD, "Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion" 141 : 876-883, 2006
• 20 Avitabile T, "Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema" 140 : 695-702, 2005
• 21 Ozkiris A, "Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion" 20 : 13-17, 2006
• 22 Noma H, "Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion" 244 : 309-315, 2006
• 23 Iturralde D, "Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study" 26 : 279-284, 2006
• 24 Avery RL, "Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy" 113 : 1695-, 2006
• 25 Rabena MD, "Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion" 27 : 419-425, 2007
• 26 Mandal S, "Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization" 17 : 620-626, 2007
• 27 Jonas JB, "Intraocular pressure elevation after intravitreal triamcinolone acetonide injection" 112 : 593-598, 2005
• 28 Krohne TU, "Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans" 146 : 508-512, 2008
• 29 Battaglia Parodi M, "Grid lasertreatment of macular edema in macular branch retinal vein occlusion" 97 : 427-431, 1999
• 30 Ferrara N, "Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer" 3 : 391-400, 2004
• 31 Rehak J, "Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities" 33 : 111-131, 2008
• 32 Silva RM, "Blood-retina barrier in acute retinal branch vein occlusion" 233 : 721-726, 1995
• 33 Stahl A, "Bevacizumab in retinal vein occlusion-results of a prospective case series" 245 : 1429-1436, 2007
• 34 Jaissle GB, "Bevacizumab for treatment of macular edema secondary to retinal vein occlusion" 103 : 471-475, 2006
• 35 Schaal KB, "Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion" 104 : 285-289, 2007
• 36 Branch Vein Occlusion Study Group, "Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial" 104 : 34-41, 1986
• 37 The Branch Vein Occlusion Study Group, "Argon laser photocoagulation for macular edema in branch vein occlusion" 98 : 271-282, 1984